157 related articles for article (PubMed ID: 30521581)
1. An evaluation roadmap for critical quality attributes from tier 1 in analytical similarity assessment.
Wu K; Pan H; Li C; Zhao Q; Wang L; Xia J
PLoS One; 2018; 13(12):e0208354. PubMed ID: 30521581
[TBL] [Abstract][Full Text] [Related]
2. On Statistical Approaches for Demonstrating Analytical Similarity in the Presence of Correlation.
Yang H; Novick S; Burdick RK
PDA J Pharm Sci Technol; 2016 11/12; 70(6):547-559. PubMed ID: 27325594
[TBL] [Abstract][Full Text] [Related]
3. On the establishment of equivalence acceptance criterion in analytical similarity assessment.
Wang T; Chow SC
J Biopharm Stat; 2017; 27(2):206-212. PubMed ID: 28051920
[TBL] [Abstract][Full Text] [Related]
4. Sample size requirement in analytical studies for similarity assessment.
Chow SC; Song F; Bai H
J Biopharm Stat; 2017; 27(2):233-238. PubMed ID: 27935446
[TBL] [Abstract][Full Text] [Related]
5. Analytical Similarity Assessment in Biosimilar Studies.
Chow SC; Song F; Bai H
AAPS J; 2016 May; 18(3):670-7. PubMed ID: 26873509
[TBL] [Abstract][Full Text] [Related]
6. On sample size requirement for analytical similarity assessment.
Zhao Y; Chang YW; Chow SC
J Biopharm Stat; 2018; 28(6):1143-1159. PubMed ID: 29513612
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of analytical similarity between trastuzumab biosimilar CT-P6 and reference product using statistical analyses.
Lee J; Kang HA; Bae JS; Kim KD; Lee KH; Lim KJ; Choo MJ; Chang SJ
MAbs; 2018; 10(4):547-571. PubMed ID: 29482416
[TBL] [Abstract][Full Text] [Related]
8. Statistical considerations regarding correlated lots in analytical biosimilar equivalence test.
Shen M; Wang T; Tsong Y
J Biopharm Stat; 2017; 27(2):213-219. PubMed ID: 27906604
[TBL] [Abstract][Full Text] [Related]
9. Development of statistical methods for analytical similarity assessment.
Tsong Y; Dong X; Shen M
J Biopharm Stat; 2017; 27(2):197-205. PubMed ID: 27977326
[TBL] [Abstract][Full Text] [Related]
10. Statistical Approaches to Assess Biosimilarity from Analytical Data.
Burdick R; Coffey T; Gutka H; Gratzl G; Conlon HD; Huang CT; Boyne M; Kuehne H
AAPS J; 2017 Jan; 19(1):4-14. PubMed ID: 27709452
[TBL] [Abstract][Full Text] [Related]
11. Biological Characterization of SB3, a Trastuzumab Biosimilar, and the Influence of Changes in Reference Product Characteristics on the Similarity Assessment.
Lee JH; Paek K; Moon JH; Ham S; Song J; Kim S
BioDrugs; 2019 Aug; 33(4):411-422. PubMed ID: 31190280
[TBL] [Abstract][Full Text] [Related]
12. Adjustment for unbalanced sample size for analytical biosimilar equivalence assessment.
Dong XC; Weng YT; Tsong Y
J Biopharm Stat; 2017; 27(2):220-232. PubMed ID: 28060570
[TBL] [Abstract][Full Text] [Related]
13. Scientific and statistical considerations in evaluating the analytical similarity of ABP 501 to adalimumab.
Sivendran R; RamÃrez J; Ramchandani M; Liu J
Immunotherapy; 2018 Aug; 10(11):1011-1021. PubMed ID: 30071739
[TBL] [Abstract][Full Text] [Related]
14. The Assessment of Quality Attributes for Biosimilars: a Statistical Perspective on Current Practice and a Proposal.
Mielke J; Innerbichler F; Schiestl M; Ballarini NM; Jones B
AAPS J; 2018 Nov; 21(1):7. PubMed ID: 30483892
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of the structural, physicochemical, and biological characteristics of SB4, a biosimilar of etanercept.
Cho IH; Lee N; Song D; Jung SY; Bou-Assaf G; Sosic Z; Zhang W; Lyubarskaya Y
MAbs; 2016; 8(6):1136-55. PubMed ID: 27246928
[TBL] [Abstract][Full Text] [Related]
16. A Novel Bootstrapping Test for Analytical Biosimilarity.
Zahel T
AAPS J; 2022 Oct; 24(6):112. PubMed ID: 36271265
[TBL] [Abstract][Full Text] [Related]
17. Rational Selection, Criticality Assessment, and Tiering of Quality Attributes and Test Methods for Analytical Similarity Evaluation of Biosimilars.
Vandekerckhove K; Seidl A; Gutka H; Kumar M; Gratzl G; Keire D; Coffey T; Kuehne H
AAPS J; 2018 May; 20(4):68. PubMed ID: 29748754
[TBL] [Abstract][Full Text] [Related]
18. Considerations of critical quality attributes in the analytical comparability assessment of biosimilar products.
Kwon O; Joung J; Park Y; Kim CW; Hong SH
Biologicals; 2017 Jul; 48():101-108. PubMed ID: 28495312
[TBL] [Abstract][Full Text] [Related]
19. Sample size calculations for the development of biosimilar products.
Kang SH; Kim Y
J Biopharm Stat; 2014; 24(6):1215-24. PubMed ID: 25032735
[TBL] [Abstract][Full Text] [Related]
20. Development of biosimilars.
Al-Sabbagh A; Olech E; McClellan JE; Kirchhoff CF
Semin Arthritis Rheum; 2016 Apr; 45(5 Suppl):S11-8. PubMed ID: 26947440
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
